Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice

Abstract

Keywords

COVID-19 psoriasis apremilast dermatology

Get full access to this article

View all access options for this article.

References

Sohrabi

Alsafi

O’Neill

et al. World Health organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71-76. doi:doi:10.1016/j.ijsu.2020.02.034

http://www.ncbi.nlm.nih.gov/pubmed/32112977

Lee

Kovarik

Tejasvi

Pizarro

Lipoff

. Telehealth: helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation. J Am Acad Dermatol. 2020;82(5):1213-1214. doi:doi:10.1016/j.jaad.2020.03.052

http://www.ncbi.nlm.nih.gov/pubmed/32229278

Johns Hopkins Coronavirus Resource Center. 2020. COVID-19 Case Tracker. Johns Hopkins University and Medicine. Accessed April 15, 2020. https://coronavirus.jhu.edu/

Crowley

Thaçi

Joly

et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310-317. doi:doi:10.1016/j.jaad.2017.01.052

http://www.ncbi.nlm.nih.gov/pubmed/28416342